Analysis of Clinical Features of Chronic Liver Disease Complicated With Hepatopulmonary Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-04-01

Study Completion Date

2024-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hepatopulmonary syndrome (HPS) has unknown pathogenesis, limited treatment and poor prognosis. The onset of HPS is insidious and easy to be ignored. Many liver diseases such as "cirrhosis and related complications" are the core characteristics of Beijing You 'an Hospital, but the clinical characteristics of HPS patients in the center are still unclear. The investigators plan to make the diagnosis of HPS among chronic liver disease patients in the hospital according to the diagnostic criteria of HPS proposed in the Practice Guidelines of the International Society of Liver Transplantation in 2016, collect clinical data of HPS participants, evaluate the severity, analyze and summarize clinical characteristics, and conduct management and follow-up. At the same time, The investigators collect blood samples for proteomics tests. In order to improve the diagnosis and treatment level of HPS.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Cohort Study on the Pathogen Spectrum of Hepatic Virus-caused Cirrhosis Complicated With Infection

NCT06279845

Liver Cirrhosis

NOT_YET_RECRUITING

Prognosis of Patients With Acute-on-chronic Liver Failure

NCT05393453

Acute-On-Chronic Liver Failure

UNKNOWN

Exploring Clinical Characteristics of Liver Disease Patients Based on Digestive Metabolic Exhaled Air

NCT06968234

Cirrhosis Microbiota Breath Tests

RECRUITING

Investigation of the Prevalence of Hepatopulmonary Syndrome in Cirrhosis Patients Caused by Hepatitis B in Western China

NCT03435406

Hepatopulmonary Syndrome

UNKNOWN

Exploring Biomarkers Predicting the Outcome of Acute-on-chronic Liver Failure

NCT02965560

Acute-On-Chronic Liver Failure Cirrhosis and Chronic Liver Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At present, the mechanism of hepatopulmonary syndrome is not clear. The researchers plan to use the extracted plasma for detection, protein extraction and quality control, and then proteolytic hydrolysis, computer detection, and bioinformatics analysis.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatopulmonary Syndrome (HPS)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chronic liver disease with hepatopulmonary syndrome

Liver disease (usually cirrhosis with portal hypertension) ；Positive CE-TTE（Contrast enhanced contrast ultrasound）；Abnormal arterial oxygenation: Alveolar-arterial oxygen gradient (AaO2) ≥ 15 mm Hg (\>20 mm Hg if age \> 64)

Proteomic sequencing

Intervention Type BIOLOGICAL

Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups

Chronic liver disease without hepatopulmonary syndrome

Liver disease (usually cirrhosis with portal hypertension) ； Negative CE-TTE

Proteomic sequencing

Intervention Type BIOLOGICAL

Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Proteomic sequencing

Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* chronic hepatitis Agreed to venous blood collection

Exclusion Criteria

* pneumonia, pulmonary vascular disease, interstitial pulmonary disease, COPD, bronchial asthma, lung cancer and other primary pulmonary diseases, acute upper gastrointestinal bleeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No